Lite Strategy

Lite Strategy EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Lite Strategy (LITS) as of Nov 20, 2026 is -2.89. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -1.33 — a change of 117.82% (lower).

EV/EBITDA

-2.89

YoY

117.82%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Lite Strategy is 2026 -2.89 . EV/EBITDA (Enterprise Value to EBITDA) of Lite Strategy was 2025 -1.33 . It decreases by 117.82% lower compared to the previous year.

The Lite Strategy EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2019
0.72 USD
Jan 1, 2020
5.50 USD
Jan 1, 2021
1.72 USD
Jan 1, 2022
1.36 USD
Jan 1, 2023
1.27 USD
Jan 1, 2024
0.20 USD
Jan 1, 2025
-1.33 USD
Jan 1, 2026
-2.89 USD
The Lite Strategy EV/EBITDA history
YEAREV/EBITDAYoY
-2.89+117.82%
-1.33-780.43%
0.20-84.67%
1.27-6.22%
1.36-21.12%
1.72-68.74%
5.50+663.84%
0.72-66.52%
2.15-141.24%
-5.22-2,422.41%
0.22-67.45%
0.69+146.71%
0.28—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lite Strategy Stock analysis

What does Lite Strategy do? MEI Pharma, Inc. develops cancer therapies, focusing on clinical drug candidates including Pracinostat, ME-344, and ME-401. Pracinostat, an HDAC inhibitor for hematologic diseases like AML and MDS, has undergone Phase I and II trials. ME-344 targets mitochondrial components in rapidly proliferating cells, while ME-401 inhibits PI3K delta for hematologic cancer treatment. The company generates revenue through clinical development and potential future drug sales, targeting oncology markets with its pipeline of cancer therapies. The firm's products are developed for specific cancer indications, with Pracinostat tested in advanced hematologic malignancies and solid tumors. ME-344 and ME-401 address unmet needs in mitochondrial and PI3K delta pathways, respectively. MEI Pharma's revenue model relies on clinical trial progress and future commercialization of these therapies, aiming to secure partnerships or direct sales in oncology. MEI Pharma's portfolio includes three clinical drug candidates, each targeting distinct cancer mechanisms. Pracinostat is advanced in trials for AML and MDS, while ME-344 and ME-401 are in development for broader cancer applications. The company monetizes through potential drug approvals and sales, with a focus on hematologic cancers and solid tumor markets. Lite Strategy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lite Strategy stock

EV/EBITDA (Enterprise Value to EBITDA) of Lite Strategy is -2.89 in 2026.

EV/EBITDA (Enterprise Value to EBITDA) of Lite Strategy changed from -1.33 to -2.89, representing a 117.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Lite Strategy since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Lite Strategy with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Lite Strategy

All Key Metrics — Lite Strategy